NCT05947201View on ClinicalTrials.gov

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

October 1, 2024

Conditions
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
Interventions
DRUG

Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil

If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma

Trial Locations (1)

0571

RECRUITING

Lulu Liu, Hanzhou

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Weijia Fang, MD

OTHER